Reviews/Novel Antibiotics/Cefiderocol achieves high cure rates in non-Acinetobacter resistant infections
Cefiderocol · NOVEL-AB-CFDC-02 · v2
Cefiderocol is a newer antibiotic for serious infections caused by bacteria that resist most existing drugs. The claim is that it cures a high share of these infections when the bug is not Acinetobacter. In the best primary data, the main randomised trial [1], cure was achieved in roughly half of patients, and a real-world study [11] found success in about the same proportion. A single markedly higher figure came from a very small 24-patient subgroup of metallo-beta-lactamase producers [13]. A matched comparison in mostly Pseudomonas infections found cefiderocol did no better than the alternative treatment and had more relapses [15]. The evidence points to cefiderocol being a reasonable option rather than a high-cure treatment, which is why the panel did not accept the word 'high'.
In the pivotal CREDIBLE-CR trial [1], clinical cure reached 50% of 40 pneumonia patients and 43% of 23 bloodstream or sepsis patients, with microbiological eradication in 53% of 17 complicated UTI patients. A pooled metallo-beta-lactamase subgroup from CREDIBLE-CR and APEKS-NP reported clinical cure of 70.8% in 24 patients [13]. A real-world immunocompromised cohort recorded clinical success of 53.3% at day 28, with relapse of 17.5% rising by a further 9.8% among survivors by day 90 [11]. A matched cohort of difficult-to-treat non-fermenters, 81.5% Pseudomonas aeruginosa, found no improvement in clinical cure over best available therapy and higher relapse [15]. The contested point: The evidence divides on whether the word 'high' is carried: the one favourable figure of 70.8% comes from just 24 patients [13], while the larger primary datasets sit near 50% [1] and 53.3% [11], and a head-to-head comparison shows no cure advantage [15]. There is directional support that non-Acinetobacter infections fare better, but in [1] this rests on where the mortality excess concentrated rather than on cure stratified by pathogen.
All 19 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Novel Antibiotics, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The pivotal RCT's cure rates are 43-53% [1] — moderate, not 'high'; the claim's load-bearing adjective is unsupported by the primary data.
CREDIBLE-CR [1] reports cure by infection site, not stratified by non-Acinetobacter pathogen; the claim's exact scope (non-Acinetobacter cure rates) is inferred from a mortality-subset comment, not measured. Indirectness.
Where it remains uncertain. A matched cohort of predominantly Pseudomonas infections found no cure improvement over best available therapy and higher relapse [15], directly countering the 'high' characterisation.
Aleatory
The 70.8% cure figure derives from only 24 patients [13], so chance variation around that estimate is large and it cannot be read as a stable population rate.
Epistemic
CREDIBLE-CR [1] reports cure by infection site, not by non-Acinetobacter pathogen, so the claim's exact population is not directly measured in the corpus.
Inferential
The non-Acinetobacter advantage in [1] is inferred from where the mortality excess concentrated ('primarily in the patient subset with Acinetobacter spp infections'), not from a cure comparison between pathogen groups.
The load-bearing papers from a corpus of 19, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal RCT cure rate ~50%, in a population only 46% Acinetobacter — moderate, not high.
“Numerically more deaths occurred in the cefiderocol group, primarily in the patient subset with Acinetobacter spp infections.”
Panel auditInternal validity: medium · scope of inference: Cefiderocol vs BAT across mixed carbapenem-resistant Gram-negative infections, pathogen subgroups not individually powered.Key limitations: open-label descriptive design · no non-Acinetobacter cure breakdown · small subgroups · numerically higher mortality
Real-world cure success only ~53% — modest.
“At day 28, clinical success was achieved in 53.3% of cases, and overall mortality was 37.7%, consistent with other studies (33-37%).”
Panel auditInternal validity: low · scope of inference: Real-world cefiderocol outcomes in immunocompromised adults with MDR infections, pathogen-pooled.Key limitations: retrospective single-arm · no non-Acinetobacter cure breakdown · sick immunocompromised population · high relapse and resistance acquisition noted
Highest cure figure, in MBL-producers (largely non-Acinetobacter); small descriptive subgroup.
“rates of clinical cure (70.8% [17/24]), microbiological eradication (58.3% [14/24]), and day 28 all-cause mortality (12.5% [3/24]) compared favorably with comparators”
Panel auditInternal validity: low · scope of inference: Cefiderocol outcomes in MBL-producing Gram-negative infections, pathogen identity not specified.Key limitations: tiny subgroup · post-hoc pooled subset · Acinetobacter status unstated
Counter-evidence: no cure advantage over BAT in mostly-Pseudomonas cohort, higher relapse.
“Clinical cure at 15 and 30-day and the in-ICU mortality was comparable between groups, however relapse was higher in the cefiderocol group”
Panel auditInternal validity: low · scope of inference: ICU patients with DTR non-fermenting Gram-negative bacteria, mostly Pseudomonas aeruginosa.Key limitations: small retrospective cohort · wide confidence intervals · comparative not absolute cure reported · higher relapse
4 of 19 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The corpus supports a relative non-Acinetobacter advantage but contradicts the literal claim of 'high' cure rates, which sit around 50% in the strongest primary data.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Pathogen-stratified cure data. Cure in the pivotal trial [1] is reported by infection site, not by non-Acinetobacter pathogen, so the claim's exact scope is never directly measured. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A prospective study reporting cefiderocol clinical cure separately for Pseudomonas, Klebsiella, Stenotrophomonas and other non-Acinetobacter pathogens.
Open question: Is cefiderocol clinical cure genuinely higher in non-Acinetobacter than Acinetobacter resistant infections? Why it is still open: The signal in [1] rests on where the mortality excess concentrated, not on cure stratified by pathogen, and no corpus study measures this directly.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19